PMID: 9547132Apr 18, 1998Paper

A 2-year study of sertraline in the treatment of obsessive-compulsive disorder

International Clinical Psychopharmacology
Steven A RasmussenK O'Connor

Abstract

The present study investigated the tolerability, safety profile, and anti-obsessional efficacy of sertraline, a selective serotonin reuptake inhibitor, during long-term treatment of patients with obsessive-compulsive disorder (OCD). Fifty-nine OCD patients who had completed a 1 year double-blind, fixed dose study comparing sertraline and placebo subsequently entered a 1-year open extension. Among the 51 patients who had been treated with sertraline during the double-blind phase, the mean total duration of sertraline treatment was 690 days. Only treatment responders who completed the 52-week double-blind treatment phase were permitted to enter the open extension. The higher rate (p < 0.02) of sertraline patients (51 out of 241) than of placebo patients (eight out of 84), who responded to treatment and entered the open-label phase is therefore consistent with the greater mean improvement observed in the sertraline group during double-blind treatment. Placebo responders differed from sertraline responders in that they were less impaired at baseline of the double-blind study [Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) of 18.5 versus 23.4] and they exhibited less improvement during double-blind treatment (-6.1 versus -11.4). In ...Continue Reading

Citations

Aug 17, 2000·Depression and Anxiety·R M Hirschfeld
Apr 17, 2001·Depression and Anxiety·D L Dunner
Jul 10, 2002·Journal of Affective Disorders·S A MontgomeryA Riley
May 15, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Filippo BogettoGiuseppe Maina
Aug 15, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·P H ThomsenC Persson
Oct 9, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·E H CookM Messig
Jan 6, 2009·Current Opinion in Psychiatry·Jacques ThuileFrédéric Rouillon
Oct 6, 2007·International Clinical Psychopharmacology·Naomi A FinebergDan J Stein
Apr 18, 2012·Antimicrobial Agents and Chemotherapy·Bing ZhaiXiaorong Lin
May 18, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Friederike RampacherMichael Wagner
Feb 28, 2007·Journal of Anxiety Disorders·Maria C ManceboJane L Eisen
Feb 15, 2015·Psychiatry Research·Naomi A FinebergUNKNOWN Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders
Nov 6, 2012·The Australian and New Zealand Journal of Psychiatry·Naomi A FinebergIlenia Pampaloni
Oct 31, 2002·Human Psychopharmacology·Johan A. Den BoerBernhard R. Slaap
Feb 7, 2008·The Cochrane Database of Systematic Reviews·G M SoomroM Oakley-Browne
Jan 9, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowUNKNOWN World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive
Mar 23, 2002·Journal of Clinical Psychopharmacology·Richard BergeronVratislav Hadrava
Feb 10, 2004·CNS Spectrums·Joseph Zohar, UNKNOWN World Council of Anxiety
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Feb 10, 2004·CNS Spectrums·John H GreistUNKNOWN World Council of Anxiety
Jul 4, 2003·Psychiatry and Clinical Neurosciences·Nahit Motavallý MukaddesNimet Kaynak
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Naomi A Fineberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.